

Pierre Pacaud

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11564703/publications.pdf>

Version: 2024-02-01

55
papers

4,562
citations

117625

34
h-index

161849

54
g-index

57
all docs

57
docs citations

57
times ranked

4671
citing authors

#	ARTICLE	IF	CITATIONS
1	Cyclic GMP-dependent Protein Kinase Signaling Pathway Inhibits RhoA-induced Ca ²⁺ Sensitization of Contraction in Vascular Smooth Muscle. <i>Journal of Biological Chemistry</i> , 2000, 275, 21722-21729.	3.4	541
2	Rho Kinases in Cardiovascular Physiology and Pathophysiology. <i>Circulation Research</i> , 2006, 98, 322-334.	4.5	484
3	Human Urotensin II-Induced Contraction and Arterial Smooth Muscle Cell Proliferation Are Mediated by RhoA and Rho-Kinase. <i>Circulation Research</i> , 2001, 88, 1102-1104.	4.5	255
4	The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. <i>Nature Medicine</i> , 2010, 16, 183-190.	30.7	234
5	Rho kinase blockade prevents inflammation via nuclear factor κ B inhibition: evidence in Crohn's disease and experimental colitis. <i>Gastroenterology</i> , 2003, 124, 1180-1187.	1.3	179
6	RhoA and Rho Kinase Activation in Human Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 1151-1158.	5.6	165
7	RhoA Expression Is Controlled by Nitric Oxide through cGMP-dependent Protein Kinase Activation. <i>Journal of Biological Chemistry</i> , 2003, 278, 9472-9480.	3.4	159
8	The role of Rho protein signaling in hypertension. <i>Nature Reviews Cardiology</i> , 2010, 7, 637-647.	13.7	142
9	Phosphorylation of Serine 188 Protects RhoA from Ubiquitin/Proteasome-Mediated Degradation in Vascular Smooth Muscle Cells. <i>Circulation Research</i> , 2005, 96, 1152-1160.	4.5	133
10	Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. <i>British Journal of Pharmacology</i> , 2005, 146, 1010-1018.	5.4	130
11	Extracellular Nucleotides Induce Arterial Smooth Muscle Cell Migration Via Osteopontin. <i>Circulation Research</i> , 2001, 89, 772-778.	4.5	110
12	Transglutaminase-dependent RhoA Activation and Depletion by Serotonin in Vascular Smooth Muscle Cells. <i>Journal of Biological Chemistry</i> , 2007, 282, 2918-2928.	3.4	106
13	Small G Proteins in the Cardiovascular System: Physiological and Pathological Aspects. <i>Physiological Reviews</i> , 2013, 93, 1659-1720.	28.8	104
14	P2Y1, P2Y2, P2Y4, and P2Y6 receptors are coupled to Rho and Rho kinase activation in vascular myocytes. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2000, 278, H1751-H1761.	3.2	99
15	Structure-activity relationships and structural conformation of a novel urotensin II-related peptide. <i>Peptides</i> , 2004, 25, 1819-1830.	2.4	95
16	Hyaluronan induces vascular smooth muscle cell migration through RHAMM-mediated PI3K-dependent Rac activation. <i>Cardiovascular Research</i> , 2006, 72, 339-348.	3.8	94
17	Ca ²⁺ channel activation and membrane depolarization mediated by Cl ⁻ channels in response to noradrenaline in vascular myocytes. <i>British Journal of Pharmacology</i> , 1991, 104, 1000-1006.	5.4	83
18	Ste20-Related Kinase SLK Phosphorylates Ser188 of RhoA to Induce Vasodilation in Response to Angiotensin II Type 2 Receptor Activation. <i>Circulation Research</i> , 2008, 102, 1265-1274.	4.5	79

#	ARTICLE	IF	CITATIONS
19	Structure-Activity Relationships of Human Urotensin II and Related Analogues on Rat Aortic Ring Contraction. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2003, 18, 77-88.	5.2	76
20	Urotensin II is a New Chemotactic Factor for UT Receptor-Expressing Monocytes. <i>Journal of Immunology</i> , 2007, 179, 901-909.	0.8	70
21	Drug-Eluting Stents in Bifurcations. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 120-126.	3.9	68
22	P2X ₇ Receptor Activation-Induced Contraction and Lysis in Human Saphenous Vein Smooth Muscle. <i>Circulation Research</i> , 1998, 83, 196-203.	4.5	66
23	Regulation of Rho Proteins by Phosphorylation in the Cardiovascular System. <i>Trends in Cardiovascular Medicine</i> , 2006, 16, 199-204.	4.9	64
24	Sildenafil Prevents Change in RhoA Expression Induced by Chronic Hypoxia in Rat Pulmonary Artery. <i>Circulation Research</i> , 2003, 93, 630-637.	4.5	63
25	Nucleotide receptor P2u partially mediates ATP-induced cell cycle progression of aortic smooth muscle cells. , 1996, 166, 57-65.		62
26	The Rho-related protein Rnd1 inhibits Ca ²⁺ -sensitization of rat smooth muscle. <i>Journal of Physiology</i> , 1999, 516, 825-834.	2.9	60
27	Structure-activity relationships of urotensin II and URP. <i>Peptides</i> , 2008, 29, 658-673.	2.4	56
28	Rho-kinase inhibitors prevent agonist-induced vasospasm in human internal mammary artery. <i>British Journal of Pharmacology</i> , 2001, 132, 302-308.	5.4	55
29	Identification of Differentially Expressed Genes in Human Varicose Veins: Involvement of Matrix Gla Protein in Extracellular Matrix Remodeling. <i>Journal of Vascular Research</i> , 2007, 44, 444-459.	1.4	53
30	Cardiac Protective Effects of <i>Moringa oleifera</i> Seeds in Spontaneous Hypertensive Rats. <i>American Journal of Hypertension</i> , 2016, 29, 873-881.	2.0	50
31	Angiotensin II induces RhoA activation through SHP2-dependent dephosphorylation of the RhoGAP p190A in vascular smooth muscle cells. <i>American Journal of Physiology - Cell Physiology</i> , 2009, 297, C1062-C1070.	4.6	49
32	Involvement of Rho GTPases and their regulators in the pathogenesis of hypertension. <i>Small GTPases</i> , 2014, 5, e983866.	1.6	48
33	AMPK Alpha 1-Induced RhoA Phosphorylation Mediates Vasoprotective Effect of Estradiol. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 2634-2642.	2.4	42
34	The Rho protein exchange factor Vav3 regulates vascular smooth muscle cell proliferation and migration. <i>Cardiovascular Research</i> , 2010, 86, 131-140.	3.8	39
35	RhoA Phosphorylation Induces Rac1 Release from Guanine Dissociation Inhibitor I β and Stimulation of Vascular Smooth Muscle Cell Migration. <i>Molecular and Cellular Biology</i> , 2010, 30, 4786-4796.	2.3	35
36	Rho exchange factors in the cardiovascular system. <i>Current Opinion in Pharmacology</i> , 2008, 8, 174-180.	3.5	34

#	ARTICLE	IF	CITATIONS
37	Urotensin II and atherosclerosis. <i>Peptides</i> , 2008, 29, 778-782.	2.4	33
38	<i>Moringa oleifera</i> Seeds Attenuate Vascular Oxidative and Nitrosative Stresses in Spontaneously Hypertensive Rats. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-10.	4.0	32
39	Structure-Activity Relationships of a Novel Series of Urotensin II Analogues: Identification of a Urotensin II Antagonist. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 7234-7238.	6.4	30
40	RhoA guanine exchange factor expression profile in arteries: evidence for a Rho kinase-dependent negative feedback in angiotensin II-dependent hypertension. <i>American Journal of Physiology - Cell Physiology</i> , 2012, 302, C1394-C1404.	4.6	30
41	The effect of PPADS as an antagonist of inositol (1,4,5)trisphosphate induced intracellular calcium mobilization. <i>British Journal of Pharmacology</i> , 1996, 119, 360-364.	5.4	26
42	Angiotensin II Activates the RhoA Exchange Factor Arhgef1 in Humans. <i>Hypertension</i> , 2015, 65, 1273-1278.	2.7	26
43	RhoA and resistance artery remodeling. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005, 288, H1051-H1056.	3.2	24
44	Release of Ca ²⁺ from intracellular store in smooth muscle cells of rat portal vein by ATP-induced Ca ²⁺ entry. <i>British Journal of Pharmacology</i> , 1994, 113, 457-462.	5.4	23
45	Mechanism of the ATP-induced rise in cytosolic Ca ²⁺ in freshly isolated smooth muscle cells from human saphenous vein. <i>Pflügers Archiv European Journal of Physiology</i> , 1995, 430, 429-436.	2.8	23
46	Stent Implantation Activates RhoA in Human Arteries: Inhibitory Effect of Rapamycin. <i>Journal of Vascular Research</i> , 2005, 42, 21-28.	1.4	22
47	Characterization of the P _{2Y} purinoceptor involved in the ATP-induced rise in cytosolic Ca ²⁺ concentration in rat ileal myocytes. <i>British Journal of Pharmacology</i> , 1996, 118, 2213-2219.	5.4	21
48	Role of Rho kinase signalling in healthy and varicose human saphenous veins. <i>British Journal of Pharmacology</i> , 2002, 137, 205-212.	5.4	21
49	Dependence of P2-nucleotide receptor agonist-mediated endothelium-independent relaxation on ectonucleotidase activity and A2A -receptors in rat portal vein. <i>British Journal of Pharmacology</i> , 1998, 123, 1732-1740.	5.4	18
50	PPADS Inhibits P2Y1 Purinoceptors in Rat Brain Capillary Endothelial Cells and in Rat Ileal Myocytes by an Indirect Mechanism. <i>Biochemical and Biophysical Research Communications</i> , 1998, 244, 332-335.	2.1	17
51	Rise in cytosolic Ca ²⁺ concentration induced by P ₂ purinoceptor activation in isolated myocytes from the rat gastrointestinal tract. <i>British Journal of Pharmacology</i> , 1996, 117, 775-780.	5.4	15
52	<i>Moringa oleifera</i> Seeds Improve Aging-Related Endothelial Dysfunction in Wistar Rats. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-9.	4.0	8
53	Direct stenting limits sirolimus-eluting stent edge neointimal thickening. <i>Journal of Vascular Surgery</i> , 2007, 46, 354-359.	1.1	6
54	Sildenafil-Induced Revascularization of Rat Hindlimb Involves Arteriogenesis through PI3K/AKT and eNOS Activation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5542.	4.1	3

#	ARTICLE	IF	CITATIONS
55	Antagonism of $\hat{1}\pm 1$ -adrenoceptor agonist-induced responses by rilmenidine in vascular smooth muscle. European Journal of Pharmacology, 1998, 341, 179-185.	3.5	2